The treatment of infections caused by enterobacteria that produce extended-spectrum β-lactamases enzymes (ESBLs) is increasingly challenging, so that the indiscriminate and exacerbated use of antibiotics has promoted bacterial resistance and dissemination of these pathogens, making the treatment of these bacteria a public health challenge. Taking into account that aminoglycosides are the antibiotics indicated f...